Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
FAQ
- What is UroGen Pharma's D&A?
- UroGen Pharma (URGN) reported D&A of $100K in Q2 2026.
- How has UroGen Pharma's D&A changed year-over-year?
- UroGen Pharma's D&A decreased by 0.0% year-over-year, from $100K to $100K.
- What is the long-term trend for UroGen Pharma's D&A?
- Over 4 years (2021 to 2025), UroGen Pharma's D&A has grown at a -18.9% compound annual growth rate (CAGR), from $804K to $347K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about UroGen Pharma's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude